<VariationArchive VariationID="2840633" VariationName="NM_004629.2(FANCG):c.692del (p.Ser231fs)" VariationType="Deletion" Accession="VCV002840633" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-17" DateCreated="2024-02-20" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3000457" VariationID="2840633">
      <GeneList>
        <Gene Symbol="FANCG" FullName="FA complementation group G" GeneID="2189" HGNC_ID="HGNC:3588" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>9p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="35073839" stop="35079942" display_start="35073839" display_stop="35079942" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="35073834" stop="35080012" display_start="35073834" display_stop="35080012" Strand="-" />
          </Location>
          <OMIM>602956</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_004629.2(FANCG):c.692del (p.Ser231fs)</Name>
      <CanonicalSPDI>NC_000009.12:35077055:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>9p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="35077056" stop="35077056" display_start="35077056" display_stop="35077056" variantLength="1" positionVCF="35077055" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="35077053" stop="35077053" display_start="35077053" display_stop="35077053" variantLength="1" positionVCF="35077052" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>S231fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.35077053del" Assembly="GRCh37">
            <Expression>NC_000009.11:g.35077053del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.12" sequenceAccession="NC_000009" sequenceVersion="12" change="g.35077056del" Assembly="GRCh38">
            <Expression>NC_000009.12:g.35077056del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007312.1" sequenceAccession="NG_007312" sequenceVersion="1" change="g.7961del">
            <Expression>NG_007312.1:g.7961del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007887.1" sequenceAccession="NG_007887" sequenceVersion="1" change="g.687del">
            <Expression>NG_007887.1:g.687del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004629.2" sequenceAccession="NM_004629" sequenceVersion="2" change="c.692del" MANESelect="true">
            <Expression>NM_004629.2:c.692del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004620.1" sequenceAccession="NP_004620" sequenceVersion="1" change="p.Ser231fs">
            <Expression>NP_004620.1:p.Ser231fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_499" sequenceAccession="LRG_499">
            <Expression>LRG_499:g.7961del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_657" sequenceAccession="LRG_657">
            <Expression>LRG_657:g.687del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_499t1" sequenceAccession="LRG_499t1">
            <Expression>LRG_499t1:c.692del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_499p1" sequenceAccession="LRG_499p1" change="p.Ser231Thrfs">
            <Expression>LRG_499p1:p.Ser231Thrfs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004629.2(FANCG):c.692del (p.Ser231fs) AND Fanconi anemia" Accession="RCV003637789" Version="1">
        <ClassifiedConditionList TraitSetID="6447">
          <ClassifiedCondition DB="MedGen" ID="C0015625">Fanconi anemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004629.2(FANCG):c.692del (p.Ser231fs) AND Fanconi anemia complementation group G" Accession="RCV004574323" Version="1">
        <ClassifiedConditionList TraitSetID="1859">
          <ClassifiedCondition DB="MedGen" ID="C3469527">Fanconi anemia complementation group G</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-11-16" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-11-16" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2024-02-20" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12552564</ID>
        </Citation>
        <DescriptionHistory Dated="2024-06-13">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="6447" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1797" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia</ElementValue>
                <XRef ID="MONDO:0019391" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
                <XRef ID="84" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi pancytopenia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi's anemia</ElementValue>
                <XRef ID="Fanconi+Anemia/2780" DB="Genetic Alliance" />
                <XRef ID="30575002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FA</ElementValue>
                <XRef Type="MIM" ID="227650" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6425" />
                <XRef ID="6425" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C0015625" DB="MedGen" />
              <XRef ID="D005199" DB="MeSH" />
              <XRef ID="MONDO:0019391" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1859" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10263" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group G</ElementValue>
                <XRef ID="MONDO:0013565" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi anemia group G</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCG</ElementValue>
                <XRef Type="MIM" ID="614082" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">FANCG-Related Fanconi Anemia</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15753" />
                <XRef ID="15753" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3469527" DB="MedGen" />
              <XRef ID="MONDO:0013565" DB="MONDO" />
              <XRef Type="MIM" ID="614082" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8289679" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="14744079|MedGen:C0015625" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004503495" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12552564</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ser231Thrfs*43) in the FANCG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCG are known to be pathogenic (PMID: 12552564). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FANCG-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FANCG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000009.11:g.35077053del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0015625" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9818618" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2024-06-17">
        <ClinVarSubmissionID localKey="NM_004629.2:c.692del|OMIM:614082" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005057698" DateUpdated="2024-06-17" DateCreated="2024-06-17" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004629.2:c.692del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614082" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9818618" TraitType="Disease" MappingType="XRef" MappingValue="614082" MappingRef="OMIM">
        <MedGen CUI="C3469527" Name="Fanconi anemia complementation group G" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8289679" TraitType="Disease" MappingType="XRef" MappingValue="C0015625" MappingRef="MedGen">
        <MedGen CUI="C0015625" Name="Fanconi anemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

